DEPTULA-HICKS DARLENE M 4

What Happened Darlene M. Deptula‑Hicks, a director at Aldeyra Therapeutics (ALDX), received two derivative stock awards on 2026-06-09 totaling 94,313 shares: 84,557 and 9,756 shares. Both awards show an acquisition price of $0.00 and are reported as derivative securities (stock option-type awards) rather than open‑market purchases or sales. These are compensation grants, not immediate cash purchases or sales.

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 11, 2026 (filed timely).
• Grant amounts: 84,557 shares (footnote F1) and 9,756 shares (footnote F2); combined = 94,313 shares.
• Acquisition price: $0.00 for both awards (derivative securities).
• Vesting/exercise terms:
  • F1 (84,557): Stock option exercisable in equal annual installments over three years of continuous service after June 9, 2026 (i.e., likely 1/3 per year).
  • F2 (9,756): Exercisable 100% on the one‑year anniversary of the grant, provided continuous service as a member of the Audit Committee through the vesting date.
• Shares owned after the transaction: Not specified in the filing.
• Transaction code: A = Award/Grant (derivative); no 10b5‑1 plan or tax‑withholding details reported.

Context These awards are routine director compensation in the form of derivative/option grants and do not represent an open‑market purchase (which some investors treat as a stronger bullish signal). Because these are subject to vesting and continuing service conditions, they do not result in immediate free trading shares unless and until exercised and any applicable restrictions lapse.